213 related articles for article (PubMed ID: 1430093)
21. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Sy RA; Bernstein R; Chynn KY; Kourides IA
J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
[TBL] [Abstract][Full Text] [Related]
22. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
24. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
26. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas.
Gasperi M; Petrini L; Pilosu R; Nardi M; Marcello A; Mastio F; Bartalena L; Martino E
J Endocrinol Invest; 1993; 16(7):541-3. PubMed ID: 8227984
[TBL] [Abstract][Full Text] [Related]
27. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas.
Somjen D; Tordjman K; Kohen F; Baz M; Razon N; Ouaknine G; Stern N
Clin Endocrinol (Oxf); 1997 May; 46(5):555-62. PubMed ID: 9231051
[TBL] [Abstract][Full Text] [Related]
28. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.
Kwekkeboom DJ; de Jong FH; Lamberts SW
J Clin Endocrinol Metab; 1989 Jun; 68(6):1128-35. PubMed ID: 2542356
[TBL] [Abstract][Full Text] [Related]
29. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
30. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide.
Chanson P; Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):62-5. PubMed ID: 1518435
[TBL] [Abstract][Full Text] [Related]
31. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide).
Caron P; Gerbeau C; Pradayrol L; Simonetta C; Bayard F
J Clin Endocrinol Metab; 1996 Mar; 81(3):1164-8. PubMed ID: 8772594
[TBL] [Abstract][Full Text] [Related]
32. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
33. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
[TBL] [Abstract][Full Text] [Related]
34. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
35. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
Faglia G; Bazzoni N; Spada A; Arosio M; Ambrosi B; Spinelli F; Sara R; Bonino C; Lunghi F
J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
[TBL] [Abstract][Full Text] [Related]
36. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
37. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
38. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
Chanson P; Weintraub BD; Harris AG
Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro.
Klibanski A; Alexander JM; Bikkal HA; Hsu DW; Swearingen B; Zervas NT
J Clin Endocrinol Metab; 1991 Dec; 73(6):1248-55. PubMed ID: 1720125
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.
Kwekkeboom DJ; Lamberts SW
Clin Endocrinol (Oxf); 1992 Feb; 36(2):171-6. PubMed ID: 1348979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
